Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07090330 · ClinicalTrials.gov registry record · Phase 2
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Oruka Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT07090330: Active Phase 2 study of Plaque Psoriasis, sponsored by Oruka Therapeutics.
NCT07090330 is a Phase 2 study of Plaque Psoriasis that is active but no longer recruiting, run by Oruka Therapeutics. The registered enrollment target is 80 participants, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07090330, a Phase 2 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Oruka Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
Primary Outcome
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG ORKA-001 Induction Dose
- DRUG ORKA-001 Maintenance Dose
Study Locations (20)
California
- Oruka Therapeutics Investigative Site - Fountain Valley
- Oruka Therapeutics Investigative Site - Los Angeles
- Oruka Therapeutics Investigative Site - San Diego
- Oruka Therapeutics Investigative Site - Santa Ana
- Oruka Therapeutics Investigative Site - Santa Monica
New York
- Oruka Therapeutics Investigative Site - New York
- Oruka Therapeutics Investigative Site - New York
Alberta
- Oruka Therapeutics Investigative Site - Edmonton
- Oruka Therapeutics Investigative Site - Edmonton
Connecticut
- Oruka Therapeutics Investigative Site - Cromwell
Florida
- Oruka Therapeutics Investigative Site - Coral Gables
Illinois
- Oruka Therapeutics Investigative Site - Rolling Meadows
Kentucky
- Oruka Therapeutics Investigative Site - Bowling Green
Maryland
- Oruka Therapeutics Investigative Site - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What the registry record for NCT07090330 still lists
NCT07090330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 414-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07090330 names 20 study sites across 14 states, led by California, New York, Alberta.
Frequently Asked Questions
What is clinical trial NCT07090330 about?
NCT07090330 is a clinical study titled "ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis". This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT07090330?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2025-07-18. Estimated completion is 2027-05.
What conditions does trial NCT07090330 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT07090330?
The interventions under investigation include: Placebo (OTHER), ORKA-001 Induction Dose (DRUG), ORKA-001 Maintenance Dose (DRUG).
Who is sponsoring clinical trial NCT07090330?
This trial is sponsored by Oruka Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07090330 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07090330's enrollment target sits among peer trials
80 33rd of 45 higher than 12 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
-
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI